Baird Maintains an 'Outperform' on Optimer Pharmaceuticals (OPTR); Q3-11: Dificid A-OK

Baird maintains an 'Outperform' on Optimer Pharmaceuticals (NASDAQ: OPTR) price target raised $1 to $19.

Baird analyst says, "Dificid sales were a little better than recent consensus, but following the 9/12 positive, partial pre-announce, we sensed investors were more focused on what Q4 might look like and on underlying demand trends. The Q3 update contained constructive datapoints and clues on underlying demand trends. We came away reinforced in thinking Q4 is tracking well and fundamental growth will remain healthy."

For more ratings news on Optimer Pharmaceuticals click here and for the rating history of Optimer Pharmaceuticals click here.

Shares of Optimer Pharmaceuticals closed at $14.47 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Canaccord Downgrades York Space Systems (YSS) to Hold, 'Supply chain and contract timing uncertainty'
• Deutsche Bank Downgrades Netskope (NTSK) to Hold on Valuation
• Deutsche Bank Downgrades SentinelOne Inc (S) to Hold on Valuation